Recent news coverage includes broad market and economic topics with limited direct company-specific news. The company held a shareholder meeting in August 2026 with election of board members.

• Nymox shareholders voted in favor of electing the board of directors in August 2026, with high shareholder participation and approval rates [S2].
• Recent market news highlights mixed stock performance amid rising bond yields and crude oil prices, with no direct impact on Nymox reported [N1].
• Discussions on social security claiming age and other macroeconomic factors were reported, unrelated to company operations [N2].
• Market volatility related to AI slowdown fears and commodity price changes was noted in September 2026, without company-specific implications [N8].

The company’s focused research and development on NX-1207 and other therapeutic candidates addresses significant medical needs in urology. Successful clinical trial results and regulatory approvals could enable product commercialization and revenue generation. The company’s strategy to partner with larger pharmaceutical firms for marketing and distribution could leverage external resources and expertise. The recent election of an experienced board of directors supports governance and strategic oversight. The company’s ability to manage operating expenses and secure financing could sustain development activities. The proprietary technologies and patents provide a foundation for potential competitive advantage [S1][S2].

The company has sustained operating losses and has not generated product revenues, reflecting the high-risk nature of clinical-stage pharmaceutical development. Liquidity ratios indicate current liabilities exceed current assets, which may constrain operational flexibility. The timing, costs, and success of clinical trials and regulatory approvals are uncertain, with potential delays or failures impacting business prospects. The company’s reliance on equity financing and partnerships introduces dilution and dependency risks. Market competition, manufacturing challenges, and regulatory hurdles add to operational risks. Cybersecurity and information risks are also noted as potential vulnerabilities [S1][S2].

Nymox Pharmaceutical Corp’s moat is primarily based on its proprietary research and development efforts in therapeutic candidates for urological conditions, including patented technologies related to NX-1207. The company’s progress through clinical trials and regulatory pathways is critical to establishing product differentiation and market entry. However, as a clinical-stage company without marketed products or revenues, its competitive position depends heavily on successful clinical outcomes, regulatory approvals, and strategic partnerships. The company’s intellectual property and licensing agreements with research institutions provide some protection for its technologies. The moat is currently limited by the early development stage and the inherent risks of pharmaceutical product development [S1].

• Clinical Development Risk: The success of the company depends on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain and may result in delays or failures.
• Liquidity and Financing Risk: Current liquidity ratios indicate limited short-term assets relative to liabilities, and the company may need to raise additional capital, which could dilute shareholders.
• Regulatory and Manufacturing Risk: Compliance with regulatory requirements and manufacturing standards (cGMP) is complex and may impact product development timelines and costs.
• Cybersecurity Risk: Potential cybersecurity breaches could compromise confidential information, damage reputation, and expose the company to liability.

• Nymox Pharmaceutical Corp is a clinical-stage pharmaceutical company focused on research and development of therapeutic products, particularly in urology (BPH and prostate cancer).
• The company has incurred substantial operating losses since inception, mainly due to R&D expenditures.
• As of December 31, 2025, the company had an accumulated deficit of $216.7 million.
• The company had no revenues from sales of goods for the years ended December 31, 2024 and 2025, reflecting its early-stage development status.
• Research and development expenditures were $1.48 million in 2025, down from $3.28 million in 2024, mainly related to advancing the NX-1207 product candidate through clinical trials.
• Marketing expenses were nil for 2024 and 2025, consistent with no marketed products.
• General and administrative expenses increased to $2.19 million in 2025 from $1.00 million in 2024, driven by stock-based compensation and professional fees.
• Finance costs increased to $587,440 in 2025 from $226,000 in 2024, mainly due to finance charges and amortization of convertible loan components.
• The company operates in the United States, Canada, and the Bahamas, with expenses incurred in local currencies.
• The company’s liquidity position as of December 31, 2024, shows cash and equivalents of $4.07 million, current assets of $653,000, and current liabilities of $7.43 million, resulting in a current ratio of 0.09 and a cash ratio of 0.55.
• The company’s board of directors includes Dr. Paul Averback (Chairman and CEO) and other members elected in August 2026.
• The company’s financial statements are prepared under IFRS and audited, with disclosures incorporated by reference in the 20-F filing.
• The company’s business model involves advancing therapeutic candidates through clinical trials and regulatory approval, with anticipated need for partnerships with larger pharmaceutical companies for commercialization.
• The company’s risk management includes oversight of cybersecurity risks by the board of directors.
• The company’s capital is primarily funded through issuance of common shares and private placements.
• The company’s operating expenses include costs for demonstrating product efficacy and regulatory compliance prior to launch.
• The company’s research and development activities include clinical trials and manufacturing considerations under cGMP standards.
• The company’s financial disclosure states that figures are summarized from latest SEC filings and provided for informational purposes only.